Supriya Lifescience files IPO papers with Sebi

By: |
May 16, 2021 4:18 PM

As of March, 2021, the company had product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

IPOFor the six months ended September 2020, the company posted a profit of Rs 25.31 crore and its revenue from operations stood at Rs 224.52 crore.

Supriya Lifescience Ltd has filed preliminary papers with capital markets regulator Sebi to raise Rs 1,200 crore through an initial public offering (IPO).

The IPO comprises fresh issue of equity shares worth Rs 200 crore and an offer for sale of up to Rs 1,000 crore by its promoter Satish Waman Wagh, according to the draft red herring prospectus (DRHP).

Proceeds from the fresh issue will be used for funding capital expenditure requirements, repay debt and general corporate purpose.

Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.

As of March, 2021, the company had product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

ICICI Securities and Axis Capital have been appointed as merchant bankers to advise the company on the IPO.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Nifty to hit 17,250 by June 2022, says ICICI Securities; SBI, HDFC Bank, GAIL among top stock picks
2Petrol, Diesel sales recover, as India eases lockdown restrictions
3Tata Motors rating: ‘Buy’. Rakesh Jhunjhunwala-owned stock may gain 15% more, debt reduction at play